A detailed history of State Street Corp transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, State Street Corp holds 396,792 shares of ADAP stock, worth $265,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares
396,792
Previous 390,901 1.51%
Holding current value
$265,850
Previous $383,000 1.83%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.92 - $1.39 $5,419 - $8,188
5,891 Added 1.51%
396,792 $376,000
Q2 2024

Aug 14, 2024

BUY
$0.83 - $1.47 $65,041 - $115,193
78,363 Added 25.07%
390,901 $383,000
Q1 2024

May 15, 2024

BUY
$0.7 - $1.75 $5,041 - $12,603
7,202 Added 2.36%
312,538 $493,000
Q4 2023

Feb 14, 2024

BUY
$0.43 - $0.79 $2,681 - $4,925
6,235 Added 2.08%
305,336 $241,000
Q3 2023

Nov 14, 2023

BUY
$0.73 - $1.04 $5,932 - $8,452
8,127 Added 2.79%
299,101 $233,000
Q2 2023

Aug 14, 2023

BUY
$0.9 - $1.51 $5,609 - $9,411
6,233 Added 2.19%
290,974 $267,000
Q1 2023

May 15, 2023

BUY
$1.06 - $2.16 $16,899 - $34,436
15,943 Added 5.93%
284,741 $310,000
Q4 2022

Feb 14, 2023

SELL
$1.05 - $2.53 $42,525 - $102,464
-40,500 Reduced 13.09%
268,798 $392,000
Q3 2022

Nov 15, 2022

SELL
$1.06 - $2.41 $60,660 - $137,917
-57,227 Reduced 15.61%
309,298 $332,000
Q2 2022

Aug 15, 2022

SELL
$1.33 - $2.28 $364,546 - $624,936
-274,095 Reduced 42.79%
366,525 $623,000
Q1 2022

May 16, 2022

BUY
$1.73 - $4.06 $44,334 - $104,045
25,627 Added 4.17%
640,620 $1.32 Million
Q4 2021

Feb 14, 2022

BUY
$3.5 - $5.68 $167,244 - $271,413
47,784 Added 8.42%
614,993 $2.31 Million
Q3 2021

Nov 15, 2021

BUY
$3.44 - $6.37 $1.06 Million - $1.96 Million
307,627 Added 118.51%
567,209 $2.94 Million
Q2 2021

Aug 16, 2021

SELL
$3.86 - $5.78 $570,913 - $854,890
-147,905 Reduced 36.3%
259,582 $1.11 Million
Q1 2021

May 17, 2021

BUY
$4.9 - $6.83 $230,368 - $321,105
47,014 Added 13.04%
407,487 $2.16 Million
Q4 2020

Feb 16, 2021

BUY
$4.0 - $9.2 $618,764 - $1.42 Million
154,691 Added 75.17%
360,473 $1.94 Million
Q3 2020

Nov 10, 2020

BUY
$7.66 - $10.78 $257,000 - $361,679
33,551 Added 19.48%
205,782 $1.64 Million
Q2 2020

Aug 14, 2020

BUY
$2.58 - $12.1 $444,355 - $2.08 Million
172,231 New
172,231 $1.72 Million

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $109M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.